Clinical trials: Hematological Neoplasm
COVID-19, Sars-CoV2
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles.
- Conditions
- COVID-19, Sars-CoV2, Cancer, Solid Tumor
- Trial name
- NCT04419623
- Testing
- TL-895
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Telios Pharma, Inc.
Hematologic Cancer, CRS - Cytokine Release Syndrome
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Aims To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications Expand the understanding of the interactions between physiology and…
- Trial name
- NCT06377059
- Testing
- WARD
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer
OctavaPink for Women With Dense Breast After Negative Mammography
The OctavaPink test is indicated as an adjunct to mammography for breast cancer screening in asymptomatic women for whom screening or diagnostic mammography findings are normal or benign (BIRADS assessment category 1 or 2) and…
- Trial name
- NCT02209389
- Testing
- MRI
- Where
- 7 sites in United States, Israel and 1 more
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Eventus Diagnostics Ltd
Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment.
- Trial name
- NCT05106374
- Testing
- Biospecimen Collection, Cognitive Assessment, Physical Performance Testing
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hematological Malignancies
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies.
- Trial name
- NCT05005442
- Testing
- Pembrolizumab/vibostolimab coformulation
- Where
- 65 sites in United States, Brazil and 14 more
- Volunteers
- 192 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancy
Effects of Parenteral Nutrition in HSCT
Nutritional therapy implementation in hematopoietic stem cell transplantation (HSCT) have undergone changes recently due to new conditioning regimen and graft versus disease prophylaxis, novel enteral and parenteral nutrition…
- Trial name
- NCT04425642
- Testing
- Glucose/Amino acids, Glucose/Amino acids/Lipids
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hematologic Malignancy
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: To assess the safety and feasibility of early CD45RA-depleted DLI administration.
- Trial name
- NCT07052370
- Testing
- Thymoglobulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Hematologic Malignancy, Lymphoma
Telerehabilitation in Hemato-oncological Survivors
This study investigates whether the 12-week home-based exercise training with remote guidance and telemonitoring compared to regular center-based training leads to better long-term cardiorespiratory fitness and physical activity…
- Trial name
- Tele@home (NCT05779605)
- Testing
- Home-based training, Center-based training
- Where
- Czechia
- Volunteers
- 80 people
- Sponsor
- Brno University Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of vorinostat when given together with cytarabine and etoposide in treating patients with relapsed or refractory acute leukemia or myelodysplastic syndromes or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00357305
- Testing
- vorinostat, cytarabine, etoposide
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies.
- Conditions
- Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05107856
- Testing
- PRT1419, Azacitidine, Venetoclax
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Prelude Therapeutics Incorporated
Hematologic Neoplasms
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
The management of hematological malignancies justifies the completion of a complete assessment before the start of treatment. This assessment includes imaging tests (computed tomography, position emission tomography, cavitary…
- Trial name
- REVEH (NCT03483194)
- Testing
- Virtual Reality, Kalinox
- Where
- 5 sites in France
- Volunteers
- 126 people
- Sponsor
- Weprom
Multiple Myeloma, Non-Hodgkin Lymphoma
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- NCT04136756
- Testing
- NKTR-255, NKTR-255 Q21, Rituximab
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
Breast Carcinoma, Esophageal Carcinoma
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT00991094
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with…
- Trial name
- NCT04588922
- Testing
- SLS009, venetoclax, azacitidine
- Where
- 32 sites in United States, China
- Volunteers
- 160 people
- Sponsor
- Sellas Life Sciences Group
Hematologic Malignancies, Myelogenous Leukemia
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00144703
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Hematological Disease
Cord Blood Transplantation for Patients With Cancer
The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.
- Trial name
- NCT01359254
- Testing
- Melphalan, Fludarabine, Antithymocyte Globulin (ATG)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Hematological Malignancy
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy involved in CNS. 20 patients were enrolled.
- Trial name
- NCT04287309
- Testing
- CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
MRD-guided Treatment in NPM1mut AML Patients
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable…
- Trial name
- PEMAZA (NCT03769532)
- Testing
- Pembrolizumab, Azacitidine
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Technische Universität Dresden
Hematological Malignancies
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological malignancies with extramedullary lesions
- Trial name
- NCT04790747
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.